NEW YORK, June 4, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Pluristem Therapeutics, Inc. ("Pluristem" or the "Company") (NasdaqCM: PSTI -News). The investigation focuses on whether the Company and its executives violated federal securities laws.
On Tuesday, June 4, 2013, shares of the Pluristem fell $0.47 or 14% during intraday trading after the Company said a mid-stage trial of its experimental muscle pain drug was put on clinical hold by the U.S. Food and Drug Administration due to a serious allergic reaction in a patient. Out of 74 patients enrolled in Pluristem's trials to date, the Company said this was the first incident of a serious allergic reaction. The patient was discharged from the hospital the following day, following the resolution of all her symptoms. Under a clinical hold, the FDA can suspend or delay an ongoing study and ask for information from the company. The FDA will issue a letter within the next 30 days detailing a list of questions and requests for information from Pluristem.
If you are aware of any facts relating to this investigation, or purchased shares of Pluristem, you can assist this investigation by contacting Peretz Bronstein, Esq. of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.